(Lumateperone Tosylate) - 药物靶点：5-HT2A receptor x D2 receptor_在研适应症：躁郁症，精神分裂症，躁郁症1型_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Lumateperone、Lumateperone tosylate (USAN)、ITI-007

+ [2]

靶点

5-HT2A receptor x D2 receptor

作用机制

5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、D2 receptor拮抗剂(多巴胺D2受体拮抗剂)

治疗领域

其他疾病神经系统疾病

在研适应症

躁郁症精神分裂症躁郁症1型+ [4]

非在研适应症

痴呆引起的激越阿尔茨海默症躁郁症2型

原研机构

Bristol Myers Squibb Co.

在研机构

Intra-Cellular Therapies, Inc.

The University of Chicago

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2019-12-20),

精神分裂症

最高研发阶段(中国)-

特殊审评快速通道 (美国)

登录后查看首次获批时间轴

结构

分子式C31H36FN3O4S

InChIKeyLHAPOGAFBLSJJQ-GUTACTQSSA-N

CAS号1187020-80-9

关联

37

项与 Lumateperone Tosylate 相关的临床试验

NCT06462612 / Not yet recruiting临床3期

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Lumateperone in the Acute Treatment of Patients With Manic Episodes or Manic Episodes With Mixed Features Associated With Bipolar I Disorder (Bipolar Mania)

This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

开始日期2024-07-01

申办/合作机构

Intra-Cellular Therapies, Inc.

NCT06462586 / Recruiting临床3期

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Lumateperone in the Acute Treatment of Patients With Manic Episodes or Manic Episodes With Mixed Features Associated With Bipolar I Disorder (Bipolar Mania)

This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

开始日期2024-06-01

申办/合作机构

Intra-Cellular Therapies, Inc.

NCT06174116 / Recruiting临床4期IIT

Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia

The main question this study is trying to answer is whether lumateperone, an FDA-approved antipsychotic drug, can help reduce possible side effects of clozapine, such as weight gain and elevated levels of sugar and bad cholesterol.
Participants will be randomly assigned to either take lumateperone (Caplyta) or a placebo for 12 weeks, in addition to their regularly prescribed clozapine. During their participation, patients will answer questions about their psychiatric and daily functioning, have blood drawn, and have their body composition analyzed (similar to stepping on a scale).

开始日期2024-04-02

申办/合作机构

Intra-Cellular Therapies, Inc.

100 项与 Lumateperone Tosylate 相关的临床结果

登录后查看更多信息

100 项与 Lumateperone Tosylate 相关的转化医学

登录后查看更多信息

100 项与 Lumateperone Tosylate 相关的专利（医药）

登录后查看更多信息

65

项与 Lumateperone Tosylate 相关的文献（医药）

2024-02-01·CNS spectrums

Lumateperone monotherapy for treatment-resistant obsessive-compulsive disorder in an adolescent

Article

作者: Elsori, Dalal ; Alamiri, Bibi ; Naguy, Ahmed ; Abuzeid, Mohamed Y ; Pridmore, Saxby

2024-01-01·International clinical psychopharmacology

Differentiating the third generation of antipsychotics: a focus on lumateperone’s similarities and differences

Review

作者: Munayco Maldonado, Gloria M ; Schwartz, Thomas L

The development of atypical antipsychotics has evolved to include newer pharmacodynamic properties. Lumateperone, aripiprazole, brexpiprazole, and cariprazine are all dopamine-2 receptor partial agonists with varying receptor affinities. This review aims to compare the clinical and pharmacodynamic differences among these four atypical antipsychotics, all of which are unique when compared to first- and second-generation antipsychotics. For consideration is further delineating these agents as being third-generation antipsychotics. PubMed searches were conducted to compile preclinical and clinical studies derived from animal models and human subjects. Information gathered included pharmacological mechanisms, clinical efficacy, future-oriented clinical approaches, and adverse effects. Efficacy for the shared indications of these drugs seems comparable. Differences among these drugs lie more in their adverse effect profiles. For example, lumateperone was found to have the lowest rate of weight gain while brexpiprazole was found to have the highest rate of weight gain associated with increased appetite. Aripiprazole had the lowest rates of extrapyramidal symptoms not including akathisia while cariprazine had the highest. All four agents reviewed have a variety of receptor affinities, which likely generates a variety of different adverse effects. This suggests that in any given patient, clinicians may see differential clinical effects.

2024-01-01·Journal of clinical psychopharmacology

Direct-to-Consumer Advertising Survey of Psychiatrists in Massachusetts and Michigan

Article

作者: Shader, Richard I ; Wechsler, Bennett E ; Rothschild, Anthony J ; Balon, Richard

Abstract:

Purposes/Background:

The goals of this preliminary study were to survey psychiatrists and to examine the impact of advertisements on their prescription of psychotropic medications. The study specifically looked at psychiatrists in Massachusetts and Michigan, as the authors were able to readily contact the members of their respective state psychiatric societies.

Methods/Procedures:

We used the survey software, Quatrics, to create an online survey that was sent via email link to the members of the Massachusetts Psychiatric Society (1400 estimated members), and the Michigan Psychiatric Society (700 estimated members). Details were obtained about how challenging it was for the psychiatrist to convince the patient that a medication was not indicated. Information regarding how the psychiatrist first heard about new medications and where they go to learn more about these medications was included in the survey.

Findings/Results:

We received 162 partial or full responses to our survey, representing a response rate of 8%. Those who were less than 10 years out of training were less likely to find it “easy” to change the minds of these patients, when compared with those more than 10 years out of training (Fisher exact test, P = 0.0396). The most frequent medication named as a response to “which medications do patients request” was Rexulti (brexpiprazole), followed by Vraylar (cariprazine), Caplyta (lumateperone), and aripiprazole.

Implications/Conclusions:

This survey points to the prevalence of psychiatrists getting requests for these advertised medications and illustrates that those with fewer years out of training may have a more difficult time redirecting patients from medications that are not indicated for their illness.

72

项与 Lumateperone Tosylate 相关的新闻（医药）

2024-06-20

·药明康德

一周缓解抑郁，疗效持续维持！小分子疗法即将递交监管申请

Intra-Cellular Therapies今天宣布在研疗法lumateperone作为抗抑郁药物的辅助治疗，在治疗抑郁症（MDD）的3期临床试验502中获得积极顶线结果。该公司预计将在2024年下半年向美国FDA提交lumateperone的补充新药申请（sNDA），作为辅助疗法治疗MDD。在502研究中，作为抗抑郁药物的辅助治疗，每日一次服用的lumateperone达到了主要终点，在第6周时与安慰剂相比，显示出在蒙哥马利-阿斯伯格抑郁评分表（MADRS）总评分上的统计学显著和具有临床意义的减少。在调整后的意向治疗（mITT）研究人群中，lumateperone组MADRS总分比基线减少14.7分，而安慰剂为10.2分（平均差异为-4.5分；p<0.0001）。值得一提的是，在第1周就观察到与安慰剂相比在MADRS总分上的数值改善（p=0.0504），并在第2周开始出现统计学显著差异，并在整个研究期间保持。 Lumateperone还达到了研究的关键性次要终点，在第6周时显示出在临床总体印象严重程度（CGI-S）评分上与安慰剂相比统计学显著和具有临床意义的减少（p<0.0001）。从第3周开始在CGI-S评分上与安慰剂相比显示出统计学显著差异，并在整个研究期间保持。在这项研究中，通过快速抑郁症状自评量表（QIDS-SR-16）测量，lumateperone显著改善了患者报告的抑郁症状（p<0.0001）。QIDS-SR-16是一种由患者评定的16项量表，用于评估抑郁症症状的严重程度。它评估了抑郁症的多个关键症状：包括失眠/嗜睡、情绪低落、食欲/体重变化、自我认知障碍、注意力困难、兴趣/愉快感丧失、自杀意念、精神运动性激越和疲劳。 Lumateperone总体安全性和耐受性良好。最常见的不良事件（≥5%且超过安慰剂两倍）是头晕、嗜睡、口干、恶心、腹泻和疲劳。不良事件大多为轻至中度，并在研究过程中自行缓解。 Lumateperone是一种口服、每日一次的非典型抗精神病药。它已经获得FDA的批准用于治疗精神分裂症以及辅助治疗成人1型或2型双相情感障碍相关的精神分裂症和抑郁发作。虽然其作用机制尚未得到完全澄清，但已知其疗效可通过中枢5-羟色胺受体2A（5-HT2A）的拮抗活性和中枢多巴胺D2受体的突触后拮抗活性联合介导。参考资料： [1] Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder. Retrieved June 18, 2024, from https://www.globenewswire.com/news-release/2024/06/18/2900311/30597/en/Intra-Cellular-Therapies-Announces-Positive-Topline-Results-in-Second-Phase-3-Trial-Evaluating-Lumateperone-as-Adjunctive-Therapy-in-Patients-with-Major-Depressive-Disorder.html 内容来源于网络，如有侵权，请联系删除。

临床结果

2024-06-18

·药明康德

潜在首款，小分子疗法递交上市申请；约12亿美元的ADC授权合作……

▎药明康德内容团队编辑约12亿美元，Day One囊获创新ADC，治疗多种实体瘤 Day One Biopharmaceuticals今天宣布已与MabCare Therapeutics公司达成独家许可协议，获得靶向蛋白酪氨酸激酶7（PTK7）的创新抗体偶联药物（ADC）MTX-13的全球独家开发、生产和商业化权利（不包括大中华区）。 2024年4月，美国FDA批准了MTX-13的IND申请，该药物未来将被称为DAY301。在临床前研究中，DAY301显示出对多种实体瘤的抗肿瘤活性。DAY301靶向的PTK7是一种高度保守的催化失活的跨膜蛋白，在多种成人癌症（包括食道癌、卵巢癌、肺癌和子宫内膜癌）以及儿童癌症（如神经母细胞瘤、横纹肌肉瘤和骨肉瘤）中高度表达。PTK7在正常组织或器官中的表达有限，使其成为ADC疗法开发的理想靶点。根据协议条款，MabCare将获得5500万美元的预付款，并有资格获得额外高达11.52亿美元的开发、监管和商业化里程碑付款。Day One预计将在2024年第四季度或2025年第一季度对首位患者进行给药。潜在首款！小分子疗法递交新药申请 KalVista Pharmaceuticals今天宣布已向美国FDA提交了口服血浆激肽释放酶抑制剂sebetralstat的新药申请（NDA），用于在12岁及以上成人和儿科患者中按需治疗遗传性血管性水肿（HAE）发作。 NDA的提交基于之前披露的临床试验结果，包括3期临床试验KONFIDENT和KONFIDENT-S扩展试验的数据。Sebetralstat在3期试验中达到了主要终点，300 mg和600 mg剂量均显著快于安慰剂开始缓解症状（300 mg p<0.0001，600 mg p=0.0013）。300 mg sebetralstat组患者接受治疗1.61小时后出现症状缓解（CI：1.28，2.27），600 mg为1.79小时（CI：1.33，2.27），安慰剂为6.72小时（CI：2.33，>12）。新闻稿指出，如果获批，sebetralstat将成为首个口服按需服用治疗HAE的药物。NDA申请包括12-17岁的患者，该公司认为这组患者因使用注射药物方面存在挑战而具有特别高的未满足需求。KalVista计划在2024年第三季度开始一项儿科试验（KONFIDENT-KID），如果成功，将在未来能够将患者覆盖范围扩展到2-11岁的患者。 AI新锐完成5000万美元融资，主打药物已进入临床开发 Iambic Therapeutics今天宣布完成5000万美元的B轮扩展融资。获得资金将用于推进Iambic的临床期和临床前项目，包括IAM1363，一种高度选择性、可穿越血脑屏障的HER2抑制剂。它可以抑制野生型和携带致癌突变的HER2受体，目前处于1/1b期研究中。获得资金还将用于开发一种潜在“first-in-class”的CDK2/4抑制剂，旨在扩大治疗窗口并解决乳腺癌等实体瘤中的耐药问题。 Iambic的候选药物是使用其AI蛋白结构预测和整体药物设计模型发现的。这些技术集成在一个闭环、自动化、高通量的生物和化学实验平台中，每周从数千种分子设计中提供新的生物学见解，从而直接为其AI模型提供信息。开发创新免疫疾病小分子疗法，赛诺菲达成约7亿美元合作 Belharra Therapeutics今天宣布与赛诺菲（Sanofi）达成战略合作，以推进创新小分子免疫疾病治疗药物的发现。该合作将利用Belharra的专有非共价化学蛋白质组学平台，对赛诺菲指定的免疫学靶点进行筛选和验证。Belharra有望获得高达4000万美元的预付款和短期里程碑付款，以及研究、开发和商业里程碑付款，总计约7亿美元。 Belharra的平台旨在提供广泛和无偏倚的化学蛋白质组学筛选能力。该平台利用一组计算设计的非共价类药物分子库，通过光亲化学（photoaffinity chemistry）来识别与特定分子结合的蛋白质以及靶蛋白上的精确结合位置。所有筛选均在天然细胞环境中进行。通过这种方法，Belharra能够揭示任何细胞类型中蛋白质-小分子或蛋白质-蛋白质相互作用的结合口袋，为发现针对难以靶向的蛋白质靶点以及创新蛋白靶点的新药提供洞见。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers. Retrieved June 18, 2024, from https://ir.dayonebio.com/news-releases/news-release-details/day-one-expands-pipeline-potential-first-class-clinical-stage [2] Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder. Retrieved June 18, 2024, from https://www.globenewswire.com/news-release/2024/06/18/2900311/30597/en/Intra-Cellular-Therapies-Announces-Positive-Topline-Results-in-Second-Phase-3-Trial-Evaluating-Lumateperone-as-Adjunctive-Therapy-in-Patients-with-Major-Depressive-Disorder.html [3] Iambic Therapeutics Closes $50 million Series B Extension to Broaden its Pipeline of AI-Discovered Clinical Oncology Programs. Retrieved June 18, 2024, from https://www.iambic.ai/post/iambic-therapeutics-closes-50-million-series-b-extension-to-broaden-its-pipeline-of-ai-discovered-clinical-oncology-programs [4] Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Small Molecule Therapeutics for Immunological Diseases. Retrieved June 18, 2024, from https://belharratx.com/press-releases/belharra-therapeutics-announces-strategic-collaboration-with-sanofi-to-advance-discovery-of-novel-small-molecule-therapeutics-for-immunological-diseases/ [5] KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema. Retrieved June 18, 2024, from https://www.businesswire.com/news/home/20240618507569/en 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床3期抗体药物偶联物临床结果引进/卖出临床成功

2024-06-18

·Firstwordpharma

Intra-Cellular's Caplyta replicates depression success with second Phase III win

Intra-Cellular Therapeutics' antipsychotic Caplyta (lumateperone) has duplicated its success in treating major depressive disorder (MDD), achieving a second Phase III win just two months after its initial triumph. The data solidifies Caplyta's efficacy and safety profile as a potential new contender in MDD, fueling blockbuster hopes for the drug.On Tuesday, Intra-Cellular reported that Caplyta met the primary and key secondary endpoints in the 480-patient Study 502 when used as an adjunct to antidepressants. The 42mg dose provided a 4.5-point reduction on the Montgomery-Åsberg Depression Rating Scale (MADRS) at week 6 compared to placebo. Patients who received Caplyta in addition to standard antidepressants achieved an MADRS improvement of 14.7 points, compared to an improvement of just 10.3 points seen with placebo."These results, further support our vision for Caplyta to become a leading option for patients and providers across mood disorders," said CEO Sharon Mates. The success follows April's first Phase III win in the Study 501 trial, where Caplyta demonstrated a 4.9-point MADRS advantage over placebo when used as adjunctive therapy to antidepressants.Buyout targetWith this second late-stage success, RBC Capital Markets analyst Brian Abrahams forecasts a "straightforward path for approval and commercialisation" in MDD that could expand Caplyta revenues with a $1.7-billion additional opportunity and bring its total US sales to more than $3 billion annually. The drug, an atypical antipsychotic of the butyrophenone class, was originally approved by the FDA in 2019 as a once-daily oral treatment for schizophrenia, and then expanded to include bipolar depression in 2021."With consistent, strong positive data...[we] see continued appreciation potential for shares to better reflect the value and scarcity of their de-risked, likely multi-blockbuster asset in the neuropsych space," Abrahams stated, suggesting a potential takeover could even emerge down the road.In an interview with FirstWord in April after the Study 501 readout, key opinion leader (KOL) Christoph Correll said the data boded well for Study 502 and that Intra-Cellular likely wouldn't need to wait for results from a third trial – the open label roll-over Study 503 assessing long-term safety – before seeking a label expansion. For more, see – KOL Views Q&A: Intra-Cellular's Caplyta emerges as a threat to the established order in MDD.Indeed, the company said it now plans to submit a supplemental new drug application for Caplyta's in MDD in the second half.Eating away at Vraylar, RexultiCaplyta also exhibited a favourable safety profile. Pooled safety data from both studies 501 and 502 showed mostly mild-to-moderate side effects like dizziness, dry mouth, somnolence and nausea that resolved over the course of the trials, Intra-Cellular said.Moreover, the lack of metabolic issues like weight gain could help differentiate it from antidepressants like AbbVie's Vraylar (cariprazine) and Rexulti (brexpiprazole) from Otsuka and Lundbeck. "Caplyta will cannibalise mostly Vraylar and Rexulti," Correll predicted. From an efficacy standpoint, Vraylar led to a 2.1- to 2.6-point improvement in symptoms compared to placebo on the MADRS scale, while Rexulti bested placebo by 2 to 3.2 points.See – KOL Views Q&A: Expert previews a changing treatment landscape ahead for MDD.

临床结果临床3期上市批准细胞疗法

100 项与 Lumateperone Tosylate 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11170	Lumateperone Tosylate	N05A	DB06077

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
躁郁症	美国	Intra-Cellular Therapies, Inc.	2021-12-17
精神分裂症	美国	Intra-Cellular Therapies, Inc.	2019-12-20

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
躁郁症1型	临床3期	美国	Intra-Cellular Therapies, Inc.	2024-06-01
躁狂	临床3期	美国	Intra-Cellular Therapies, Inc.	2024-06-01
痴呆引起的激越	临床3期	美国	Intra-Cellular Therapies, Inc.	2016-08-29
阿尔茨海默症	临床3期	美国	Intra-Cellular Therapies, Inc.	2016-08-29
躁郁症2型	临床3期	美国	Intra-Cellular Therapies, Inc.	2015-12-15
重度抑郁症	临床3期	美国	Intra-Cellular Therapies, Inc.	2015-12-15
边缘性人格障碍	临床2期	美国	The University of Chicago	2023-05-10
边缘性人格障碍	临床2期	美国	Intra-Cellular Therapies, Inc.	2023-05-10
分裂情感性障碍	临床1期	美国	Intra-Cellular Therapies, Inc.	2021-03-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05061706 (ITI-007-502, Company_Website) 人工标引	临床3期	重度抑郁症新辅助	480	Lumateperone 42 mg	窪衊衊觸顧襯觸淵願夢(壓廠醖夢憲築築選艱膚) = 壓製獵襯壓糧網願醖憲醖選廠鑰壓構獵蓋鑰衊 (艱鏇齋衊鏇壓構醖範範 ) 达到	积极	2024-06-18
				Placebo	窪衊衊觸顧襯觸淵願夢(壓廠醖夢憲築築選艱膚) = 築選鏇壓憲獵廠鏇襯觸醖選廠鑰壓構獵蓋鑰衊 (艱鏇齋衊鏇壓構醖範範 ) 达到
NCT04985942 (Corporate Publications) 人工标引	临床3期	重度抑郁症	485	Lumateperone 42 mg	淵窪構艱蓋網繭艱簾憲(齋餘襯衊顧窪衊淵糧齋) = 淵襯襯淵觸襯鹽壓淵窪遞襯餘遞鹹艱觸製鑰醖 (構積簾簾築衊鑰壓淵範 ) 达到	积极	2024-04-16
Study 403 (GlobeNewswire) 人工标引	N/A	躁郁症2型 \| 重度抑郁症 \| 躁郁症1型	-	Lumateperone 42mg (combined mixed features patient population of MDD and bipolar depression)	憲淵齋鏇衊齋襯繭夢範(鹹網艱遞觸糧網夢獵壓) = 夢餘廠衊糧鏇糧繭蓋積製網觸願遞壓選憲壓築 (衊艱膚憲願蓋築選糧淵, 0.64)	积极	2023-12-05
				Lumateperone 42mg (MDD with mixed features)	憲淵齋鏇衊齋襯繭夢範(鹹網艱遞觸糧網夢獵壓) = 窪網觸遞壓選選願獵鹽製網觸願遞壓選憲壓築 (衊艱膚憲願蓋築選糧淵, 0.67)
Study 403 (GlobeNewswire) 人工标引	N/A	重度抑郁症 \| 躁郁症	-	Lumateperone (MDD/bipolar depression)	艱鹽衊糧簾鬱範齋糧鏇(餘觸鬱鹹簾醖獵壓蓋選) = 夢製製壓鬱鹹鑰鑰夢願獵顧選膚夢積壓憲鏇齋 (繭壓繭齋簾窪憲憲鹹觸, 0.67)	积极	2023-12-05
NCT02600507 (CTgov)	临床3期	躁郁症2型 \| 重度抑郁症	529	Lumateperone (ITI-007) (Lumateperone 28 mg (ITI-007 40 mg Tosylate))	網築選廠獵憲網衊鬱顧(簾壓蓋餘遞淵積壓衊鹹) = 顧襯鏇衊觸繭網製願觸構網廠鹹窪鹹壓夢鬱膚 (窪鹽鬱廠窪鹹遞齋廠網, 膚範衊壓繭願艱鹽鹹網 ~ 膚顧廠夢夢鏇願製廠窪) 更多	-	2023-05-17
				Lumateperone (ITI-007) (Lumateperone 42 mg (ITI-007 60 mg Tosylate))	網築選廠獵憲網衊鬱顧(簾壓蓋餘遞淵積壓衊鹹) = 壓衊艱廠製鹽夢選顧憲構網廠鹹窪鹹壓夢鬱膚 (窪鹽鬱廠窪鹹遞齋廠網, 製憲廠憲築遞顧構鏇鬱 ~ 窪蓋廠顧選鏇鏇獵顧蓋) 更多
NCT03249376 (CTgov)	临床3期	躁郁症2型 \| 重度抑郁症	381	Lumateperone (Lumateperone)	襯鹽選艱網蓋膚範鹹鏇(窪餘願範廠網選鏇簾製) = 積觸廠齋築憲簾淵艱鹽構餘壓構壓積鏇壓壓夢 (觸襯鹽衊網鹹淵顧膚壓, 繭餘夢醖願繭觸窪顧鏇 ~ 衊製鏇衊遞壓構網鏇簾) 更多	-	2022-06-03
				Placebo (Placebo)	襯鹽選艱網蓋膚範鹹鏇(窪餘願範廠網選鏇簾製) = 壓鹹顧簾鬱憲齋鑰窪夢構餘壓構壓積鏇壓壓夢 (觸襯鹽衊網鹹淵顧膚壓, 顧夢窪艱淵艱築衊餘鹽 ~ 淵齋糧夢網網窪夢壓齋) 更多
NCT03249376 (Pubmed \| Am J Psychiatry)	临床3期	躁郁症2型 \| 躁郁症1型 \| 重度抑郁症	381	Lumateperone 42 mg/day	獵積壓衊觸構願網顧衊(構膚鹹網觸醖膚齋廠壓) = Nausea occurred with lumateperone at a clinically meaningful greater rate than placebo 淵顧淵顧簾鬱衊夢鑰製 (膚築鑰築鬱艱構夢築壓 ) 更多	积极	2021-12-01
NCT03817528 (CTgov)	临床2期	精神分裂症	4	ITI-007	鹽鹽製糧繭醖壓鏇願遞(鹹淵積構鹹襯遞獵衊鹹) = 襯醖襯積餘蓋鹹範廠簾衊繭網艱齋糧壓網顧觸 (夢齋壓願範觸積壓壓獵, 鏇顧積鬱獵獵構遞顧鬱 ~ 觸膚衊艱夢鬱製壓憲鏇) 更多	-	2021-11-02
NCT02817906 (CTgov)	临床3期	阿尔茨海默症 \| 痴呆引起的激越	177	Placebo	觸齋願顧鹹願網鏇顧鹹(構築簾構衊觸夢廠製蓋) = 艱鬱廠襯壓夢簾窪範積製築壓鹹製觸餘廠築構 (齋廠糧鏇衊鑰齋襯鬱衊, 網獵鬱糧積餘鏇觸膚鬱 ~ 廠夢壓簾鹹願遞糧憲積) 更多	-	2021-06-29
NCT03249376 (Study 404, Pubmed) 人工标引	临床3期	抑郁辅助	377	Lumateperone	簾夢構構廠衊簾淵遞憲(鹽簾壓鏇製築繭艱艱壓): difference = -4.6 (95% CI, -6.34 ~ -2.83), P-Value = <0.0001	积极	2021-04-01
				Placebo